HFB200301-hIgG1

TNFR2, belonging to the TNFR family of costimulatory molecules, presents an appealing target for T-cell co-stimulation due to its expression on tumor-infiltrating lymphocytes across a diverse spectrum of tumors. HFB200301, a pioneering agonistic anti-TNFR2 antibody, exhibits potent and selective binding to TNFR2, prompting the activation of CD4 T cells, CD8 T cells, and NK cells. Distinguished by its unique mechanism of action, HFB200301 relies predominantly on its agonistic activity across various effector cell types within the tumor microenvironment. We anticipate that this novel approach will yield benefits for a patient population identified by a distinctive biomarker signature.